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Although neurotrophins have been postulated to have antidepres-
sant properties, their effect on anxiety is not clear. We find that
transgenic overexpression of the neurotrophin BDNF has an un-
expected facilitatory effect on anxiety-like behavior, concomitant
with increased spinogenesis in the basolateral amygdala. More-
over, anxiogenesis and amygdalar spinogenesis are also triggered
by chronic stress in control mice but are occluded by BDNF over-
expression, thereby suggesting a role for BDNF signaling in stress-
induced plasticity in the amygdala. BDNF overexpression also
causes antidepressant effects, because transgenic mice exhibit
improved performance on the Porsolt forced-swim test and an
absence of chronic stress-induced hippocampal atrophy. Thus,
structural changes in the amygdala and hippocampus, caused by
genetic manipulation of the same molecule BDNF, give rise to
contrasting effects on anxiety and depressive symptoms, both of
which are major behavioral correlates of stress disorders.
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Prolonged and severe stress is associated with various cognitiveand affective behavioral abnormalities. The hippocampus,
which plays an important role in the formation of declarative
memories, has been the primary focus of research on the cognitive
effects of chronic stress (1). From a cell biological perspective, a
reduction in the length and complexity of dendritic arbors of
hippocampal CA3 pyramidal neurons is a well characterized mor-
phological feature of various rodent models of repeated stress (2).
This stress-induced dendritic remodeling, in turn, has been hypoth-
esized to underlie the hippocampal volume loss (3, 4) seen in
patients suffering from various stress-related disorders, including
major depression, Cushing’s syndrome, and posttraumatic stress
disorder (5–7). Recent evidence has pointed to neurotrophins as a
cause for these changes and have led to the ‘‘neurotrophic hypoth-
esis,’’ which states that symptoms associated with depression, both
pathological and behavioral, are a result of decreased neurotrophic
support, and conversely, that increasing neurotrophic support
would lead to the resolution of these symptoms (8, 9).
Although hippocampal plasticity has, over the years, provided a
useful framework for studying the cognitive effects of stress at
multiple levels of neural organization, the affective aspects of stress
disorders, such as increased anxiety, are likely to involve the
amygdala, which plays a pivotal role in processing aversive experi-
ences (10, 11). Interestingly, in contrast to the hippocampus, which
inhibits the hypothalamic–pituitary–adrenal (HPA) axis, the amyg-
dala stimulates it (12). In addition, pathological anxiety disorders
are associated with an increase in amygdalar volume and output
(13–16). Analogously, in rodents, the same chronic immobilization
stress (CIS) that causes hippocampal atrophy can elicit dendritic
growth in the basolateral amygdala (BLA), as well as enhanced
anxiety-like behavior (17–19). These crucial differences between
the hippocampus and amygdala indicate that previous studies
examining the hippocampus have provided an incomplete view of
stress-related disorders. In contrast to the hippocampus, the roles
of neurotrophins in chronic stress-induced modulation of amyg-
dalar pyramidal cell structure and anxiety-like behavior have not
been resolved. Hence, we sought to extend the neurotrophic
hypothesis into anxiety disorders, which share considerable comor-
bidity with depression (14, 20, 21). To this end, we used genetically
modified mice overexpressing BDNF in excitatory neurons of the
forebrain (22), including the hippocampus, cortex, and amygdala.
Becausemany antidepressants are also effective in reducing anxiety
(23), we predicted that genetic overexpression of BDNFwould also
protect against chronic stress-induced anxiety.
Results
Transgenic Mice Overexpress BDNF in the Hippocampus and Amyg-
dala. To verify that BDNF-overexpressing transgenic mice have
up-regulated BDNF levels in the hippocampus and basolateral
amygdala (BLA), we conducted ELISA analysis on tissue isolated
from the two regions. In parallel, Western blot analysis using
antibodies against the BDNF receptor trkB was also performed to
determine whether up-regulation of BDNF led to any compensa-
tory changes in trkB. There were significantly higher levels of
BDNF in both the hippocampus (controls, 0.43  0.03 pgg
protein; transgenics, 3.4 0.4 pgg protein; n 6; P 0.01) and
BLA (controls, 0.29  0.04 pgg protein; transgenics, 3.6  1.5
pgg protein; n  6; P  0.01) of transgenic animals. Although
there was a trend toward higher trkB levels in the hippocampus,
there was no statistically significant difference between trkB levels
in the control and transgenic animals in either the hippocampus
(controls, 1.0  0.2; transgenics, 1.5  0.3; data normalized to
control animals; n  6, P  0.2) or the BLA (controls, 1.0  0.2;
transgenics, 1.1  0.1; data normalized to control animals; n  6,
P  0.2). Thus, BDNF levels were higher, without compensatory
decreases in trkB levels, in both the hippocampus and the BLA of
the transgenic mice.
BDNF-Overexpressing Transgenic Mice Show Increased Anxiety. As
mentioned earlier, BDNF has been identified as a candidate
antidepressant, and although depression and anxiety share consid-
erable comorbidity, and many antidepressants also act as anxiolyt-
ics, the effect of BDNF on anxiety has not been determined. Thus,
we sought to determine the effect of enhanced BDNF signaling on
anxiety using chronic stress models known to facilitate anxiety-like
behavior in rodents (17, 24–26). To this end, we first examined
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anxiety-like behavior of controlB6mice exposed toCIS (2 hper day
for 10 days), along with unstressed littermate mice, by subjecting
them to the open-field test.As shown inFig. 1aLeft, control stressed
animals spent significantly less time in the center of the apparatus,
confirming data from the literature that chronic stress leads to
increased anxiety. To our surprise, levels of anxiety displayed by
unstressed transgenic animals were statistically indistinguishable
from those of the stressed control animals (Fig. 1a Left). Further,
exposure to CIS failed to trigger any additional statistically signif-
icant increase in anxiety in the transgenic mice. When we analyzed
the behavior of the mice during the course of the entire 10-min
session in the open-field test, we found that the unstressed control
mice spent increasingly more time in the center of the arena. By
contrast, the stressed control and transgenic mice, irrespective of
whether they were stressed, occupied primarily the periphery of the
arena during the first fewminutes and continued to do so during the
10-min session (Fig. 1a Right). Importantly, although CIS increased
locomotor activity consistent with data from the literature (27), our
results are not likely to be caused by such changes in locomotor
activity, because the stressed control and transgenic animals did not
display hyperactivity after the first 3 min of the test (Fig. 1b Right),
whereas the decreased occupancy of the center of the apparatus by
the stressed control, unstressed transgenic, and stressed transgenic
mice occurred primarily after those first 3 min had elapsed (Fig. 1a
Right).
As a further confirmation that the transgenic mice exhibited
greater anxiety evenwithout exposure to chronic stress, control and
transgenic mice were subjected to the elevated plus-maze test. We
found that the transgenic mice spent less time in the open arm as
compared to the controls (Fig. 1c Left). Importantly, there was no
difference in the number of closed-arm entries (Fig. 1c Right),
indicating that differences in locomotor activity were not respon-
sible for the observed differences between the two groups. Thus,
results obtained from the open-field and the elevated plus-maze
Fig. 1. Forebrain BDNF overexpression
increases anxiety and spine density in the
BLA. (a) CIS causes a decrease in amount
of time spent in the center of the open-
field apparatus. This is seen both in mean
time spent in the center of the apparatus
(Left) and when the behavior of the ani-
mals is quantified during the entire 10
min of the test (Right). Transgenic mice
show the same decrease in time spent in
the center of the open field and have no
further decrease in time spent in the cen-
ter when subjected to CIS. (b) CIS causes
an increase in locomotor activity, but
there is no genotype effect. Furthermore,
after 3 min of the test, there is no differ-
ence in total movement time between
any of the groups, indicating that
changes in locomotor activity are not re-
sponsible for the differences in anxiety
between groups seen in a. (c) Elevated-
plus maze data show that transgenic mice
spend significantly less time in the open
arm compared to control animals (Left).
There is no change in activity levels as
measured by number of closed-arm en-
tries (Right). (d) Representative photomi-
crographs of apical dendritic spines from
BLA pyramidal neurons of control and
transgenic mice, with and without stress.
(Scale bar, 10 m.) (e) In control animals,
CIS causes a significant increase in apical
spine density, when the mean spine den-
sity (Left) along the whole dendrite is
considered, or in the distal portion of the
dendrite, when segmental analysis is per-
formed (Right). ( f) In transgenic animals,
there is no significant change in spine
density, either in overall mean values
(Left) or when segmental analysis is per-
formed (Right). (g) BDNF overexpression
leads to the same increase in spine-
density as chronic stress. This is shown in
both overall mean spine density and seg-
mental analysis (*, P  0.05; **, P  0.01;
***, P  0.001; at the right in a, b, and g,
when any statistical significance is noted,
it is between the unstressed control
group and the least different of the
stressed control group and unstressed
transgenic group, which are statistically
indistinguishable from each other). (h)
Correlation analysis shows that mean spine density is strongly correlated with anxiety, as measured by time spent in the center of the open field (R  0.7,
P  0.01).
Govindarajan et al. PNAS  August 29, 2006  vol. 103  no. 35  13209
N
EU
RO
SC
IE
N
CE
paradigms both demonstrated greater anxiety in the BDNF-
overexpressing mice relative to control animals. Importantly, the
BDNF-overexpressing animals had the same level of anxiety as
stressed control animals and were not susceptible to any further
increase in anxiety upon exposure to chronic stress.
BDNF-Overexpressing Transgenic Mice Show Increased BLA Spine
Density. We next sought to elucidate the cellular substrate behind
the enhanced anxiety. Asmentioned earlier, the amygdala, a critical
component of the neural circuitry underlying fear, is activated by
chronic stress. Furthermore, previous studies have reported that
chronic stress-induced anxiety is accompanied by increases in
dendritic area and spine density in the BLA (17–19, 28). Because
BDNF promotes dendritic and spine growth (29), we postulated
that BDNF overexpression may mimic the effects of chronic stress
on amygdalar neuronal morphology, and that this structural re-
modeling may serve as a substrate for the enhanced anxiety
displayed by the transgenic animals. To quantify the structural
changes, we performed morphometric analysis of Golgi-
impregnated (30) spiny pyramidal neurons (Fig. 1d) of the BLA.
Compared to unstressed control mice, there was a significant
increase in BLA apical dendritic spine density in stressed control
mice (Fig. 1e Left). A more detailed segmental analysis (Fig. 1e
Right) showed a trend toward higher spine density along the entire
length of the apical dendrite in stressed animals, with statistically
significant changes in the distal portion of the dendrite. There was
also a significant increase in basal dendrite spine density. Segmental
analysis showed an increase in spine density in BLA pyramidal
neurons derived from stressed animals along the entire length of the
basal dendrite (Fig. 4a, which is published as supporting informa-
tion on the PNAS web site), with statistically significant changes in
the proximal portion of the dendrite. This confirms previous results,
obtained in rats, on enhanced synaptic connectivity of excitatory
neurons located at the input interface of the amygdala as a result
of chronic stress (28).
However, the BDNF-overexpressing transgenic mice showed no
chronic stress-induced changes in apical dendritic spine density
either in overall mean spine density or when more detailed seg-
mental analysis of dendrites was used (Fig. 1f). There was also no
difference between the unstressed and stressed transgenic animals
with respect to spine density of the basal dendrites (Fig. 4b).
Interestingly, the spine density of both the unstressed and stressed
transgenic animals was the same as that of the stressed control
animals, when both overall mean spine density (Fig. 1g Left) and
individual segments were examined, in the apical (Fig. 1g Right) as
well as the basal dendrites (Fig. 4c). Thus, paralleling our obser-
vations on anxiety-like behavior described earlier, both chronic
stress and BDNF overexpression led to enhanced spine density in
BLA pyramidal neurons, such that BDNF overexpression occluded
any additional stress-induced increase in BLA spine density. This is
consistent with the view that chronic stress mediates its effects on
anxiety by BLA spinogenesis, and that this process shares common
molecular mechanism with the BDNF pathway.
If BLA spinogenesis is indeed the substrate underlying enhanced
anxiety seen in the stressed control and BDNF-overexpressing
animals, a comparison of the spine density measured in individual
animals with the anxiety exhibited by them should reflect a corre-
lation. Behavioral and cellular data obtained from animals in all
four experimental groups displayed a strong correlation between
mean spine density on BLA apical dendrites and behavioral anxiety
(Fig. 1h), supporting a role for increased spine density in the
facilitation of anxiety triggered by both chronic stress and BDNF
overexpression. There was also a strong correlation of anxiety with
overall mean spine density of the basal dendrites (Fig. 4d).
In contrast, there was no difference in dendritic arborization of
BLA spiny pyramidal neurons between the four groups; neurons
derived from unstressed control, stressed control, unstressed trans-
genic, and stressed transgenic animals had the same total dendritic
length and number of branch points along the entire length of the
apical dendrite (Fig. 5 a–c, which is published as supporting
information on the PNAS web site). This result is consistent with
a recent report in rats demonstrating that stress can lead to
spinogenesis, as well as enhanced anxiety, even in the absence of
dendritic remodeling (28).
Anxiogenic Effect of BDNF Overexpression Is Not the Result of
Increased Stress Response. We next decided to examine the mech-
anism by which BDNF mimics the facilitatory effects of chronic
Fig. 2. Forebrain BDNF overexpression does not affect com-
monly used endocrine indicators of stress level in response to
CIS. (a and b) Forebrain BDNF overexpression does not affect
chronic stress-induced increases in blood plasma concentra-
tions of ACTH (a) and corticosterone (b). (a) In unstressed
animals, there is no significant difference between control
and transgenic animals in ACTH concentration. Chronically
stressed animals have a significant increase in ACTH concen-
tration compared to unstressed animals, but again there is
no significant genotype difference. (b) In unstressed ani-
mals, there is a significant difference between control and
transgenic animals in corticosterone levels. Chronically
stressed animals have a significant increase in corticosterone
concentration, but there is no genotype effect. (c) There is no
difference in body weight between unstressed control and
unstressed transgenic mice. (d and e) Forebrain BDNF over-
expression does not affect chronic stress-induced weight
loss. Unstressed control and transgenic animals show no
change in weight, whereas stressed control and transgenic
animals show significant weight loss at both 6 days (d) and 11
days (e) after the onset of chronic stress. There is no geno-
type effect in either unstressed or stressed animals (*, P 
0.05 between unstressed and stressed animals; ‡, P 0.05 in
a comparison between unstressed control and unstressed
transgenic animals).
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stress on anxiety and BLA spine formation. Specifically, two
alternate hypotheses were tested. First, in view of the potent role of
the HPA axis and glucocorticoids in stress-induced modulation of
neuronal morphology and behavior (31), it is possible that the role
of BDNF is to increase the stimulatory effect of the amygdala on
the HPA axis, thereby increasing the secretion of stress hormones
and causing chronic stress-induced changes throughout the brain.
The alternate explanation would entail a role for BDNF that is
downstream of glucocorticoid secretion, thereby playing a more
direct role within the amygdala.
We differentiated between these two hypotheses by measuring,
1 day after the end of the 10-day CIS protocol, the blood plasma
levels of adrenocorticotropic hormone (ACTH) and corticoste-
rone, two common indicators of HPA axis activation. Fig. 2a shows
that there was no significant difference in ACTH concentration
between unstressed control and unstressed transgenic animals. CIS
increased the levels of ACTH in both control and transgenic
animals, but there was no significant effect of genotype. Although
corticosterone levels were slightly, but significantly, lower in un-
stressed transgenic animals as compared to unstressed control
animals, there was no difference between stressed control and
stressed transgenic mice (Fig. 2b). Thus, BDNF overexpression in
forebrain excitatory cells has no effect on stress hormone levels in
animals that have undergone chronic stress.
The stress hormone data indicate that the increase in anxiety and
BLA spine density observed in the transgenic mice is not caused by
an increase in the levels of stress due to hyperactivity of the HPA
axis. This conclusion was strengthened by analysis of body weight,
because loss in body weight is another key measure of stress. We
observed no difference in body weight between the transgenic and
control mice in the absence of stress (Fig. 2c). When we analyzed
the temporal profile of weight loss that the animals undergo during
the course of 10 days of CIS, a significant decrease in the body
weight of both control and transgenic animals was evident both 6
and 11 days after the beginning of the stress protocol (Fig. 2 d and
e). However, there was no statistically significant genotype effect
observed in the experiment. Thus, these data, taken together with
the neuroendocrine data, indicate that the anxiogenic effects of
BDNF in the transgenic mice are not due to variations in stress
levels between mice of the two genotypes, as measured by common
indicators of stress.
BDNF Overexpression Prevents Chronic Stress-Induced CA3 Dendritic
Atrophy. Our results described above showed that genetic overex-
pression of BDNF can mimic the effects of repeated behavioral
stress, which is in stark contrast to the neurotrophic hypothesis (8,
9) that predicts that BDNF overexpression should counteract the
effects of chronic stress. Because the neurotrophic hypothesis was
formulated with a focus on depressive symptoms and chronic
stress-induced hippocampal damage, rather than anxiety behavior
and amygdalar hypertrophy, we wanted to examine whether the
original neurotrophic hypothesis still holds in our BDNF-
overexpressing transgenic mice. For this purpose, we focused on a
well established cellular correlate of stress-induced plasticity in the
hippocampus, dendritic remodeling of CA3 pyramidal neurons
after exposure to chronic stress (2). We subjected the brains from
unstressed control, stressed control, unstressed transgenic, and
stressed transgenic animals to Golgi–Cox histology (30) 1 day after
the end of the CIS protocol. As depicted in Fig. 3a, and in
agreement with earlier studies in rats (2), CIS induced a significant
atrophy of the apical dendritic tree of CA3 pyramidal cells in
control animals, when total dendritic length (Fig. 3b Left) or
number of branch points (Fig. 3c Left) was quantified. Scholl’s
analysis indicated, as shown in Fig. 3 b Right and c Right, that the
decrease in dendritic length andnumber of branch points in stressed
control animals compared to unstressed control animals were most
Fig. 3. Forebrain BDNF overexpression prevents chronic stress-induced dendritic atrophy in the hippocampus and reduces immobility in the Porsolt forced-swim test.
(a) Representative camera lucida tracings of CA3 pyramidal neurons from control and BDNF-overexpressing transgenic mice with and without stress. (Scale bar, 50m.)
(b and c) Effects of CIS on CA3 apical dendritic morphology in control mice. (Left) Mean values for dendritic length (b) and number of branch points (c) in a 50-m shell
as a function of the radial distance from the soma. (Right) These mean values are computed by averaging across incremental steps of 50m along the apical dendrites
using Sholl’s analysis. (*, P 0.05; **, P 0.01; ***, P 0.001). (d and e) Effects of CIS on CA3 apical dendritic morphology in transgenic mice. (Left) Mean values for
dendritic length (d) and number of branch points (e) in a 50-m shell as a function of the radial distance from the soma. (Right) These mean values are computed by
averaging across incremental steps of 50m along the apical dendrites using Sholl’s analysis. (f ) Forebrain BDNF overexpression improves performance on the Porsolt
forced-swim test. On both day 1 and day 2, the transgenic animals show less immobility as compared to control littermates (*, P 0.05 between control and transgenic
animals for each day; †, P0.01 between days 1 and 2 for control animals; ‡, P0.01 between days 1 and 2 for transgenic animals). (g) Forebrain BDNF overexpression
improves performance in the Porsolt forced-swim test when the difference in immobility between days 2 and 1 is considered. CTL, control; TG, transgenic (*, P 0.05).
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pronounced only in apical dendritic segments 50 m away from
the soma, corresponding to the stratum radiatum of area CA3. In
contrast, there was no change in either the dendritic length or
number of branch points in the basal dendrites, which is in
agreement with earlier studies using rats (2).
Having established the efficacy of the CIS paradigm in eliciting
dendritic atrophy in control mice, we next analyzed its impact on
littermate transgenic mice. In agreement with the original neuro-
trophic hypothesis, we found no differences between the morphol-
ogy of CA3 pyramidal cells in unstressed and stressed transgenic
animals (Fig. 3 a, d Left, and e Left), either in dendritic length or
number of branch points. Sholl’s analysis also confirmed there was
no change in dendritic length or number of branch points anywhere
along the length of the dendrite (Fig. 3 d and e).
BDNF-Overexpressing Transgenic Mice Exhibit Improved Performance
on Porsolt Forced-Swim Test. Because we obtained evidence that
BDNF overexpression prevents chronic stress-induced hippocam-
pal damage, we next examined whether BDNF overexpression
would also improve a behavioral symptom of depression, another
key facet of the neurotrophic hypothesis (8, 9). To this end, we used
the Porsolt forced-swim test that has been a commonly used
behavioral paradigm for depression in rodents, and one that has
been shown to be robust in the C57BL6 strain of mice (32), in
which background the transgenicmice were engineered (22). In this
test, rodents exposed to an inescapable container of water display
an immobile posture after initial escape-oriented behavior. This
immobility increases during reexposure to the same container 24 h
later. This enhanced immobility, which can be blocked by antide-
pressant treatment, is thought to represent a state of behavioral
despair that is characteristic of depression (32, 33). As shown in Fig.
3f, compared to control mice, the transgenic mice exhibited signif-
icantly decreased immobility both on day 1 and day 2 of the
forced-swim test. Furthermore, the difference in immobility be-
tween the 2 days was significantly lower in the transgenic animals
as compared to the control mice (Fig. 3g). There was no difference
in locomotor activity between control and transgenicmice (Fig. 1b),
indicating that the decreased immobility displayed by the mice was
not due to increased hyperactivity. Thus, the decreased immobility
shown by the transgenic mice is consistent with an antidepressant
effect of BDNF, as proposed by the neurotrophic hypothesis.
Hence, increasing BDNF function seems to be able to prevent
symptoms associated with depression at both the cellular and
behavioral levels.
Discussion
BDNF Overexpression, Amygdalar Structural Plasticity, and Facilitated
Anxiety. Using genetically engineered mice, we have shown that
BDNF overexpression can lead to increased anxiety, in a manner
mimicking and occluding chronic stress-induced anxiety. Further-
more, this increase in anxiety is paralleled by an increase in BLA
spine density, also similar to and occluding the effects of chronic
stress. Although our data do not exclude the possibility that the
occlusion of chronic stress-induced anxiogenesis may be caused by
a ‘‘ceiling’’ effect, whereby no further increase in anxiety is seen
after chronic stress in the transgenic animals simply because the
animals are incapable of expressing any more anxiety, the strong
correlation between spine density and anxiety lends support to our
interpretation of the data that anxiety is mediated by increased
spine density in the amygdala. Furthermore, this hypothesis is
supported by recent evidence from the literature correlating
changes in amygdalar spine density with changes in anxiety in rats
(28). This increase in amygdalar spine density may be a cause of the
increased amygdalar size and functional output, which has been
reported by several investigators studying depression and anxiety in
humans (13–16).
It has been suggested that the hippocampus might mediate
anxiety-like behaviors (34, 35). Because overexpression of BDNF
counteracts the effects of chronic stress in the hippocampus,
whereas it facilitates anxiety even in the absence of stress, it is
unlikely that hippocampal atrophy is the cellular substrate for the
anxiety seen in the transgenic mice. In addition, some manipula-
tions that reverse hippocampal atrophy, such as antidepressant
treatment and stress-free recovery, fail to prevent stress-induced
anxiety and structural plasticity in the amygdala (19, 24). Mice
overexpressing BDNF specifically in the hippocampus or amygdala
will be useful to gain further insight into this issue. Interestingly, it
was recently found that BDNFmRNA is elevated transiently in the
basolateral amygdala 2 h after cued fear conditioning (36). This
temporally restricted elevation of BDNF mRNA level and BDNF
signaling in the amygdala observed after the formation of a
cue-specific fear is in contrast to the chronic up-regulation ofBDNF
protein exhibited by the transgenic mice used here, which may
underlie the cue-nonspecific and generalized fear, or anxiety,
observed in our transgenic mice.
BDNF Overexpression and the Neurotrophic Hypothesis.Wehave also
demonstrated in this report that up-regulating BDNF can pre-
vent chronic stress-induced atrophy of hippocampal CA3 pyra-
midal cells, which has been postulated as the underlying cause of
the smaller hippocampal volumes seen in patients suffering from
posttraumatic stress disorder, Cushing’s syndrome, and major
depression (3–7, 9). In addition, these mice exhibited decreased
immobility in the forced-swim test, suggesting they are less
susceptible to depression (32, 33). Thus, our results support the
neurotrophic hypothesis by demonstrating that BDNF, elevated
chronically through genetic manipulation, can act as an antide-
pressant and protect against stress-induced hippocampal atro-
phy. In addition, our data provide genetic evidence linking
structural plasticity in the hippocampus with depressive
behavior.
Interestingly, anxiety disorders and depression share consider-
able comorbidity, and several antidepressants have been used in the
treatment of anxiety. Thus, although the neurotrophic hypothesis
was formulated with a focus on depression, it was thought that
neurotrophin up-regulation could also be used in the treatment of
anxiety. However, our data indicate that, whereas BDNF can
ameliorate depressive symptoms, it increases anxiety-like symp-
toms. Thus, we suggest that BDNF plays different roles in depres-
sion and anxiety, namely, locally in the hippocampus to inhibit
depressive symptoms and locally in the amygdala to facilitate
anxiety-like symptoms. These results with BDNF suggest that,
unless antidepressants have a differential effect in the hippocampus
and amygdala, they would not be expected to be effective anxiolytic
drugs. Consistent with this view, some clinical reports indicate that
anxiety actually increases upon initiation of certain types of anti-
depressant treatments (37). Based on our cellular data, we suggest
that differences in the action of such drugs on depression versus
anxiety are a consequence of their differential actions on the
hippocampus and amygdala.
Forebrain BDNF Overexpression and Its Effects on the HPA Axis.What
are the functional implications of BDNF overexpression with
respect to the response to chronic stress? We found there was no
difference in HPA axis regulation in the transgenic mice, except for
a small decrease in corticosterone levels in unstressed transgenic
animals. This indicates that the role of BDNF in ameliorating the
debilitating effects of stress is downstream of the stress hormones,
and thus the impact of elevated stress hormones can be reversed
without affecting the normal endocrine response to stress. This is
further supported by the data that body-weight loss, which is
governed by the hypothalamus, occurs to a similar extent in both
control and transgenic animals. Interestingly, similar to the neu-
roendocrine and body-weight changes that occur in response to
chronic stress, chronic stress-induced increases in locomotor activ-
ity also occur in both control and transgenic animals, suggesting that
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the up-regulation of locomotor activity by chronic stress occurs
independently of the morphological changes that take place in the
forebrain due to BDNF overexpression. This functional specificity
of BDNF’s effects, consistent with the regional specificity of the
pattern of overexpression in the transgenic mice, may be important
therapeutically, because modulation of stress hormones is required
for normal cognitive function (2). In other words, therapeutic
interventions that act downstream of stress hormones, such as the
BDNF pathway, may allow for a more attractive strategy for
resolving depressive symptoms without adversely affecting cogni-
tion. However, as our results show, not all of these pathways may
be therapeutically useful, because theymay have deleterious effects,
such as increased anxiety. It is desirable to identify components
further downstream of BDNF that are involved more specifically in
depression or anxiety.
In conclusion, our data, obtained from a single genetically
engineered mouse strain, provide evidence of BDNF-induced
facilitation of amygdalar spinogenesis and promotion of anxiety. In
addition, our results establish a correlation among chronic BDNF
up-regulation at the molecular level, prevention of stress-induced
hippocampal atrophy at the cellular level, and improvement in the
resolution of depressive symptoms at the behavioral level, thereby
providing comprehensive evidence spanning multiple levels of
neural organization in support of the neurotrophic hypothesis of
depression (8, 9). Our results point to the inherent difference
between the hippocampus and amygdala in manifesting the diverse
emotional symptoms related to mood disorders. Therefore, eluci-
dation of the mechanisms behind the differential effects of chronic
stress andmolecules such as BDNF on hippocampal and amygdalar
plasticity would provide further insights into novel therapeutic
targets that selectively ameliorate the varied symptoms of affective
disorders.
Methods
CIS.Male transgenic and control littermates were divided randomly
into stressed and unstressed groups. CIS was performed on the
stressed group by using rodent immobilization bags. Blood for
hormone level quantification was obtained on day 11, and ACTH
and corticosterone measurements were performed by Analytics
(Bethesda, MD). All procedures were performed in accordance
with National Institutes of Health guidelines and after approval by
the Massachusetts Institute of Technology Committee for Animal
Care.
Morphological Analysis.Mice were killed under deep anesthesia and
processed for Golgi staining technique as described (38, 39). Ten
pyramidal neurons from the CA3 region and five or six pyramidal
cells from the BLA were selected from each animal for analysis
based on established morphological criteria (40). Sholl’s analysis
used a segment diameter of 50 m for CA3 pyramidal neurons and
20m for BLA neurons. For segmental analysis of amygdalar spine
density, 8-m segments were used (39, 41).
Behavior. In the Porsolt forced-swim test, mice were forced to swim
for 5 min on 2 consecutive days in a beaker of water (diameter, 13
cm; temperature, 23–25°C). Mice were marked as immobile if they
performed theminimal amount ofwork required to float for at least
1 sec. For the open-field test, the mice were tested for 10 min by
using the Accuscan system (Dayton, OH) according to the manu-
facturer’s instructions. The elevated-plus maze apparatus consisted
of two open arms (30 5 cm) and two closed arms (wall height, 10
cm) elevated 60 cm in the air. The test lasted 10 min. Experiments
in which control animals exhibited open-arm time  30% were
discarded. At least 10 animals of each genotype were used for each
behavioral test, and no animal underwent more than one behav-
ioral test.
ELISA and Western Blot Analysis. For ELISA analysis of BDNF
levels, the hippocampus and amygdala were dissected frommice on
day 11 and processed for BDNFELISA by using the BDNFELISA
Kit according to the manufacturer’s instructions (Promega, Mad-
ison, WI). Western blot analysis was performed as described (42).
Statistical Analysis. For hormone analysis, weight measurements,
and pooled morphometric analysis, two-way ANOVA was used
with the Tukey post hoc test. For time-based analysis and segmen-
talSholl’s analysis, a three-way ANOVA was performed with the
timesegment factor used as a within-subject repeated measure.
For the ELISA data, Porsolt forced-swim test, and elevated-plus
maze tests, a Mann–Whitney test was used. Statistics were per-
formed by using SPSS software (SPSS, Chicago, IL).
Additional Methods. For additional methods, see Supporting Text,
which is published as supporting information on the PNASweb site.
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